AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34097055 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerometer monitoring of physical activity levels
Number of subjects: 15
Study 34097055 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Physical Performance Battery scores
Number of subjects: 15
Study 34097071 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone-corticotropin-releasing hormone (Dex/CRH) test
Number of subjects: 40
Study 34097071 — intervention group
Group type: COMPARATOR
Intervention: Control group (women without depression)
Number of subjects: 40
Study 34097100 — intervention group
Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil (FTD/TPI) at a dose of 35 mg/m²
Number of subjects: 43
Study 34097307 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative intensity-modulated radiotherapy (IMRT)
Number of subjects: 76
Study 34097449 — intervention group
Group type: EXPERIMENTAL
Intervention: Probabilistic readjudication of hospitalization events
Number of subjects: 0
Study 34097852 — intervention group
Group type: EXPERIMENTAL
Intervention: KTE-X19
Number of subjects: 71
Study 34098066 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning model using resting-state and task-based fMRI datasets
Number of subjects: 0
Study 34098740 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex (as an independent variable)
Number of subjects: 16821
Study 34098895 — intervention group
Group type: EXPERIMENTAL
Intervention: K-001 (1350 mg to 2160 mg, administered twice daily in four-week cycles)
Number of subjects: 12
Study 34098897 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro Hand S robot-assisted TME (RTME)
Number of subjects: 105
Study 34098897 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic TME (LTME)
Number of subjects: 105
Study 34098916 — intervention group
Group type: EXPERIMENTAL
Intervention: Key social network members (SNMs) identified by MSM
Number of subjects: 565
Study 34098916 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussions about HIV and STI prevention with SNMs
Number of subjects: 565
Study 34098916 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussions about HIV/STI prevention among trans women
Number of subjects: 565
Study 34098916 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived support for condom use among MSM SNMs
Number of subjects: 565
Study 34098916 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived support for HIV/STI testing among trans women SNMs
Number of subjects: 565
Study 34098916 — intervention group
Group type: EXPERIMENTAL
Intervention: Support for partner STI notification among MSM SNMs
Number of subjects: 565
Study 34098916 — intervention group
Group type: EXPERIMENTAL
Intervention: Support for partner STI notification among trans women SNMs
Number of subjects: 565
Study 34098916 — intervention group
Group type: EXPERIMENTAL
Intervention: Reported condomless anal intercourse (CAI)
Number of subjects: 565
Study 34098916 — intervention group
Group type: EXPERIMENTAL
Intervention: Association between SNM characteristics and CAI
Number of subjects: 565
Study 34098967 — intervention group
Group type: COMPARATOR
Intervention: Patients without treatment limitation
Number of subjects: 526
Study 34098967 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with any treatment limitation
Number of subjects: 526
Study 34098967 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment limitations (PTL)
Number of subjects: 526
Study 34098979 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm-leg pulley system
Number of subjects: 8
Study 34098979 — intervention group
Group type: COMPARATOR
Intervention: Normal walking
Number of subjects: 8
Study 34098992 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 0
Study 34098992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34099056 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week dietary restriction protocol (300 kcal/day reduction)
Number of subjects: 29
Study 34099056 — intervention group
Group type: COMPARATOR
Intervention: Control group (metabolic status maintenance)
Number of subjects: 29
Study 34099131 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP titrated to match pleural pressure (6 ± 2 cmH₂O)
Number of subjects: 12
Study 34099131 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal BMI participants)
Number of subjects: 12
Study 34099325 — intervention group
Group type: EXPERIMENTAL
Intervention: gp120 envelope protein variants
Number of subjects: 0
Study 34099325 — intervention group
Group type: EXPERIMENTAL
Intervention: Platform development strategy
Number of subjects: 0
Study 34099518 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubeless, on-body automated insulin delivery system with customizable glycemic targets
Number of subjects: 235
Study 34099518 — intervention group
Group type: COMPARATOR
Intervention: Usual insulin regimen (2-week standard therapy phase)
Number of subjects: 235
Study 34099530 — intervention group
Group type: EXPERIMENTAL
Intervention: Manganese-enhanced MRI (MEMRI)
Number of subjects: 40
Study 34099530 — intervention group
Group type: COMPARATOR
Intervention: Late gadolinium enhancement (LGE)
Number of subjects: 40
Study 34099718 — intervention group
Group type: EXPERIMENTAL
Intervention: neoadjuvant eribulin therapy
Number of subjects: 35
Study 34099923 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV positive individuals
Number of subjects: 0
Study 34099923 — intervention group
Group type: COMPARATOR
Intervention: People without HIV
Number of subjects: 0
Study 34099953 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual lymphatic drainage treatment
Number of subjects: 34
Study 34099953 — intervention group
Group type: EXPERIMENTAL
Intervention: Connective tissue techniques
Number of subjects: 34
Study 34099953 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation protocol (Control)
Number of subjects: 34
Study 34100024 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of SARS-CoV-2 antibodies
Number of subjects: 204
Study 34100024 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral RNA levels
Number of subjects: 204
Study 34100024 — intervention group
Group type: EXPERIMENTAL
Intervention: Virus-targeted treatment and prevention strategies
Number of subjects: 204
Study 34100124 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung ultrasound (LU) examination
Number of subjects: 877
Study 34100124 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 877
Study 34100292 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34100558 — intervention group
Group type: EXPERIMENTAL
Intervention: Early postnatal discharge
Number of subjects: 9409
Study 34100767 — intervention group
Group type: EXPERIMENTAL
Intervention: SleepFit application (v2.0)
Number of subjects: 56
Study 34100767 — intervention group
Group type: EXPERIMENTAL
Intervention: SleepFit application (from alpha to v1.0)
Number of subjects: 56
Study 34101002 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with LCZ696 vs. enalapril
Number of subjects: 7156
Study 34101090 — intervention group
Group type: EXPERIMENTAL
Intervention: RNA-pulsed dendritic cell vaccines
Number of subjects: 0
Study 34101090 — intervention group
Group type: EXPERIMENTAL
Intervention: RNA-loaded nanoparticle vaccines
Number of subjects: 0
Study 34101138 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.07 mg LOR
Number of subjects: 231
Study 34101138 — intervention group
Group type: COMPARATOR
Intervention: PBO
Number of subjects: 231
Study 34101502 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedural intervention for uterine fibroids
Number of subjects: 0
Study 34101537 — intervention group
Group type: EXPERIMENTAL
Intervention: Ask Suicide-Screening Questions (ASQ)
Number of subjects: 1324
Study 34101537 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Health Questionnaire (PHQ)
Number of subjects: 1324
Study 34101626 — intervention group
Group type: EXPERIMENTAL
Intervention: DS003 (BMS-599793)
Number of subjects: 0
Study 34101701 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual orientation concealment
Number of subjects: 0
Study 34101701 — intervention group
Group type: EXPERIMENTAL
Intervention: Internalized homophobia
Number of subjects: 0
Study 34101701 — intervention group
Group type: EXPERIMENTAL
Intervention: Transactional sex
Number of subjects: 0
Study 34102018 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril-valsartan (SV) for 3 months
Number of subjects: 118
Study 34102349 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib 420 mg orally once daily (reduced to 280 mg/d with voriconazole)
Number of subjects: 19
Study 34102857 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional denervation volume
Number of subjects: 0
Study 34102857 — intervention group
Group type: COMPARATOR
Intervention: Global parameters of sympathetic innervation
Number of subjects: 0
Study 34102857 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine analog imaging
Number of subjects: 0
Study 34102902 — intervention group
Group type: EXPERIMENTAL
Intervention: 32-mm metal head
Number of subjects: 96
Study 34102902 — intervention group
Group type: COMPARATOR
Intervention: 36- to 44-mm metal head
Number of subjects: 96
Study 34103005 — intervention group
Group type: EXPERIMENTAL
Intervention: GEnetic Syntax Score (GESS) risk prediction algorithm based on genetic markers and clinical information.
Number of subjects: 1080
Study 34103005 — intervention group
Group type: EXPERIMENTAL
Intervention: Next generation sequencing (NGS) technology to genotype 228 SNPs associated with CAD.
Number of subjects: 1080
Study 34103005 — intervention group
Group type: EXPERIMENTAL
Intervention: SYNTAX score calculation for assessment of CAD severity based on angiographic findings.
Number of subjects: 1080
Study 34103005 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up for one year to record major adverse cardiovascular events.
Number of subjects: 1080
Study 34103022 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved chicken management practices
Number of subjects: 973
Study 34103022 — intervention group
Group type: EXPERIMENTAL
Intervention: Having a chicken coop
Number of subjects: 973
Study 34103022 — intervention group
Group type: EXPERIMENTAL
Intervention: Enclosed chicken coop
Number of subjects: 973
Study 34103022 — intervention group
Group type: EXPERIMENTAL
Intervention: Coops that were enclosed, had fencing, and were located further from homes
Number of subjects: 973
Study 34103022 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct observations of chicken coops
Number of subjects: 973
Study 34103022 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of livestock and domestic animals inside homes
Number of subjects: 973
Study 34103022 — intervention group
Group type: EXPERIMENTAL
Intervention: In-depth interviews with child caregivers
Number of subjects: 973
Study 34103176 — intervention group
Group type: EXPERIMENTAL
Intervention: T2DM group
Number of subjects: 60
Study 34103176 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 34103352 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab 1500 mg given every 4 weeks until progression or unacceptable toxicity (dMMR cohort)
Number of subjects: 71
Study 34103352 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab 1500 mg given every 4 weeks until progression or unacceptable toxicity (pMMR cohort)
Number of subjects: 71
Study 34103352 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab (dMMR cohort)
Number of subjects: 71
Study 34103352 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab (pMMR cohort)
Number of subjects: 71
Study 34103352 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab (both cohorts)
Number of subjects: 71
Study 34103993 — intervention group
Group type: EXPERIMENTAL
Intervention: ERAS protocol
Number of subjects: 130
Study 34103993 — intervention group
Group type: COMPARATOR
Intervention: Conventional perioperative care program
Number of subjects: 130
Study 34104033 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue light therapy (BLT) for 6 weeks
Number of subjects: 28
Study 34104033 — intervention group
Group type: COMPARATOR
Intervention: Amber light therapy (ALT) for 6 weeks
Number of subjects: 28
Study 34104395 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 76
Study 34104395 — intervention group
Group type: COMPARATOR
Intervention: Control group (no zoledronic acid)
Number of subjects: 76
Study 34104395 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (zoledronic acid and control)
Number of subjects: 76
Study 34104466 — intervention group
Group type: EXPERIMENTAL
Intervention: Polar V800
Number of subjects: 144
Study 34104466 — intervention group
Group type: EXPERIMENTAL
Intervention: eMotion Faros 360
Number of subjects: 144
Study 34104466 — intervention group
Group type: EXPERIMENTAL
Intervention: TomTom heart rate monitor
Number of subjects: 144
Study 34104466 — intervention group
Group type: EXPERIMENTAL
Intervention: Adidas miCoach Smart Run
Number of subjects: 144
Study 34104466 — intervention group
Group type: COMPARATOR
Intervention: Routine electrocardiograms
Number of subjects: 144
Study 34104849 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined EPA+DHA intake (median daily intake 70 mg, IQR: 32, 145 mg)
Number of subjects: 7365
Study 34104852 — intervention group
Group type: EXPERIMENTAL
Intervention: LP + Bar
Number of subjects: 8
Study 34104852 — intervention group
Group type: EXPERIMENTAL
Intervention: HP
Number of subjects: 8
Study 34104852 — intervention group
Group type: COMPARATOR
Intervention: LP
Number of subjects: 8
Study 34104878 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma (CP) therapy, transfusion in three doses of 3 mL/kg of recipient body weight at 2-day intervals
Number of subjects: 0
Study 34104878 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma (CP) therapy
Number of subjects: 0
Study 34105200 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass Drug Administration (MDA)
Number of subjects: 13322
Study 34105303 — intervention group
Group type: EXPERIMENTAL
Intervention: bDMARDs initiated within 3 months of baseline assessment
Number of subjects: 400
Study 34105303 — intervention group
Group type: COMPARATOR
Intervention: bDMARDs initiated after 3 months from baseline assessment
Number of subjects: 400
Study 34105303 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 400
Study 34105312 — intervention group
Group type: EXPERIMENTAL
Intervention: Early combination plan (DMARD and biologic started together)
Number of subjects: 400
Study 34105312 — intervention group
Group type: COMPARATOR
Intervention: Step-up plan (initial nonbiologic DMARD monotherapy)
Number of subjects: 400
Study 34105312 — intervention group
Group type: COMPARATOR
Intervention: Biologic first plan (biologic monotherapy)
Number of subjects: 400
Study 34105312 — intervention group
Group type: EXPERIMENTAL
Intervention: Early combination plan
Number of subjects: 400
Study 34105312 — intervention group
Group type: COMPARATOR
Intervention: Step-up plan
Number of subjects: 400
Study 34105312 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 400
Study 34105902 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient trauma treatment
Number of subjects: 23
Study 34105902 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group (n = 37)
Number of subjects: 23
Study 34106085 — intervention group
Group type: EXPERIMENTAL
Intervention: Wireless home blood pressure monitoring
Number of subjects: 42
Study 34106085 — intervention group
Group type: EXPERIMENTAL
Intervention: Wireless home blood pressure monitoring with financial incentives
Number of subjects: 42
Study 34106085 — intervention group
Group type: COMPARATOR
Intervention: Usual care (nonwireless home blood pressure monitoring)
Number of subjects: 42
Study 34106597 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-cohort registry respondents (AF patients who did not consent for 24 month follow up)
Number of subjects: 1568
Study 34106597 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort registry respondents (AF patients who consented for 24 month follow up)
Number of subjects: 1568
Study 34107166 — intervention group
Group type: EXPERIMENTAL
Intervention: Napabucasin (240 mg twice daily; days 1-11)
Number of subjects: 30
Study 34107398 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-63733657 (tau mAb)
Number of subjects: 0
Study 34107506 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-child dyads, siblings, and parent-parent dyads during different time segments of the week.
Number of subjects: 1576
Study 34107506 — intervention group
Group type: EXPERIMENTAL
Intervention: Total family physical activity during late weekdays and weekends.
Number of subjects: 1576
Study 34107506 — intervention group
Group type: EXPERIMENTAL
Intervention: Light physical activity and walking behaviors.
Number of subjects: 1576
Study 34107510 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 36
Study 34107510 — intervention group
Group type: COMPARATOR
Intervention: Men
Number of subjects: 36
Study 34107510 — intervention group
Group type: EXPERIMENTAL
Intervention: Both men and women
Number of subjects: 36
Study 34107742 — intervention group
Group type: EXPERIMENTAL
Intervention: Microvascular disease (MVD) defined as the presence of ≥1 of nephropathy, retinopathy, or neuropathy at baseline (n=1424, 34.8%)
Number of subjects: 4095
Study 34107742 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephropathy (type of MVD)
Number of subjects: 4095
Study 34107742 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinopathy (type of MVD)
Number of subjects: 4095
Study 34107742 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropathy (type of MVD)
Number of subjects: 4095
Study 34107771 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplant (alloBMT) with continuous antiretroviral therapy
Number of subjects: 0
Study 34107771 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative viral outgrowth assay
Number of subjects: 0
Study 34107841 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-weeks of progressive resistance training (3 sessions per week, 4 lower body exercises, 2-4 sets of 8-15 repetitions at 60-75% of 1-repetition maximum)
Number of subjects: 18
Study 34107841 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-weeks of progressive resistance training
Number of subjects: 18
Study 34107914 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based nursing intervention including usual care, an informational booklet from NCI, and three meetings with a nurse interventionist during radiation treatment followed by a booster call two weeks posttreatment.
Number of subjects: 180
Study 34107914 — intervention group
Group type: COMPARATOR
Intervention: Usual care and an informational booklet from NCI.
Number of subjects: 180
Study 34108134 — intervention group
Group type: EXPERIMENTAL
Intervention: GAPS-EUS assessment tool
Number of subjects: 22
Study 34108167 — intervention group
Group type: EXPERIMENTAL
Intervention: CT perfusion (CTP) imaging at the time of first imaging on hospital admission
Number of subjects: 200
Study 34108167 — intervention group
Group type: COMPARATOR
Intervention: Bedside clinical assessment for brainstem function
Number of subjects: 200
Study 34108168 — intervention group
Group type: EXPERIMENTAL
Intervention: IA injection of triamcinolone acetonide
Number of subjects: 20
Study 34108168 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline urinary tests and dried blood spot tests
Number of subjects: 20
Study 34108929 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal Gene Therapy
Number of subjects: 0
Study 34108929 — intervention group
Group type: COMPARATOR
Intervention: Natural History
Number of subjects: 0
Study 34108964 — intervention group
Group type: EXPERIMENTAL
Intervention: Lentiviral vectors pseudotyped with Influenza B hemagglutinins (IBV PV)
Number of subjects: 0
Study 34108964 — intervention group
Group type: COMPARATOR
Intervention: Classical methods (hemagglutination inhibition assay and serial radial hemolysis assay)
Number of subjects: 0
Study 34109185 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative/Neoadjuvant Therapy and Vascular Debranching followed by Resection
Number of subjects: 0
Study 34109223 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum Uric Acid levels
Number of subjects: 0
Study 34109243 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone 2403 mg/day
Number of subjects: 0
Study 34109243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34109306 — intervention group
Group type: EXPERIMENTAL
Intervention: C-IVIG (0.15 g/kg)
Number of subjects: 50
Study 34109306 — intervention group
Group type: EXPERIMENTAL
Intervention: C-IVIG (0.20 g/kg)
Number of subjects: 50
Study 34109306 — intervention group
Group type: EXPERIMENTAL
Intervention: C-IVIG (0.25 g/kg)
Number of subjects: 50
Study 34109306 — intervention group
Group type: EXPERIMENTAL
Intervention: C-IVIG (0.30 g/kg)
Number of subjects: 50
Study 34109306 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 50
Study 34109306 — intervention group
Group type: EXPERIMENTAL
Intervention: C-IVIG (all dosage arms)
Number of subjects: 50
Study 34109306 — intervention group
Group type: EXPERIMENTAL
Intervention: C-IVIG
Number of subjects: 50
Study 34109484 — intervention group
Group type: EXPERIMENTAL
Intervention: FCN-437c 50 mg
Number of subjects: 17
Study 34109484 — intervention group
Group type: EXPERIMENTAL
Intervention: FCN-437c 100 mg
Number of subjects: 17
Study 34109484 — intervention group
Group type: EXPERIMENTAL
Intervention: FCN-437c 200 mg
Number of subjects: 17
Study 34109484 — intervention group
Group type: EXPERIMENTAL
Intervention: FCN-437c 300 mg
Number of subjects: 17
Study 34109484 — intervention group
Group type: EXPERIMENTAL
Intervention: FCN-437c 450 mg
Number of subjects: 17
Study 34109484 — intervention group
Group type: EXPERIMENTAL
Intervention: FCN-437c (all doses)
Number of subjects: 17
Study 34109515 — intervention group
Group type: EXPERIMENTAL
Intervention: WBRT + sorafenib (200 mg daily for 21 days)
Number of subjects: 13
Study 34109515 — intervention group
Group type: COMPARATOR
Intervention: WBRT
Number of subjects: 13
Study 34109624 — intervention group
Group type: EXPERIMENTAL
Intervention: HC-1119 at doses of 40, 80, 160, and 200 mg/day (part A)
Number of subjects: 43
Study 34109624 — intervention group
Group type: EXPERIMENTAL
Intervention: HC-1119 at doses of 80 and 160 mg (part B)
Number of subjects: 43
Study 34110001 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial injury (intentional damage to the endometrium)
Number of subjects: 8786
Study 34110001 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention or a sham procedure)
Number of subjects: 8786